Fernanda Waechter

ORCID: 0000-0003-2034-5690
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pharmaceutical studies and practices
  • Carcinogens and Genotoxicity Assessment
  • Natural product bioactivities and synthesis
  • Effects and risks of endocrine disrupting chemicals
  • Safe Handling of Antineoplastic Drugs
  • Tannin, Tannase and Anticancer Activities
  • Pharmaceutical industry and healthcare
  • Crystallization and Solubility Studies
  • Computational Drug Discovery Methods
  • Plant biochemistry and biosynthesis
  • Analytical Methods in Pharmaceuticals
  • Analytical Chemistry and Chromatography
  • Natural Compounds in Disease Treatment
  • Biological Activity of Diterpenoids and Biflavonoids

Universidade de São Paulo
2024

Stratophase (United Kingdom)
2023

Universidade Federal do Rio Grande do Sul
2017

The increased usage of purge arguments for demonstrating control mutagenic impurities in drug substances, accordance with ICH M7, necessitates an increasingly standardized approach to their implementation across industry. strength the is highly reliant upon a conservative principles maintain regulatory confidence. Different parameters may influence calculation, such as reactivity, solubility, and volatility. While reactivity data are commonly available literature, there comparatively fewer...

10.1021/acs.oprd.2c00360 article EN cc-by-nc-nd Organic Process Research & Development 2023-03-14

Chronic myeloid leukemia (CML) is currently treated with imatinib, a Bcr-Abl inhibitor. However, resistance to this drug usually develops over time. Triptolide, diterpenoid triepoxide, has been shown active against CML cells resistant acting mainly on the level of transcription inhibition.Here, we used triterpene betulinic acid, known proteasome inhibitor potential antileukemic activity, as scaffold for generation analogues predicted triptolide biological activity.Betulinic acid derivatives...

10.2174/1871521409666170412143638 article EN Anti-Cancer Agents in Medicinal Chemistry 2017-05-04

The Drug and Therapeutics Bulletin has accused the drug company Novartis of breaching advertising regulations in its advertisement for pimecrolimus, a new cream treating dermatitis (2003;41(5):33-6). A recent review by bulletin resulted three criticisms. main concern was that while licence limits use to patients aged 2 years older, advertisement, published many medical journals, shows baby who looks younger than years, implying could be used on babies below age. is consequently demanding...

10.1136/bmj.326.7399.1106-b article EN BMJ 2003-05-22
Coming Soon ...